Aytu Biopharma vs Journey Medical
Aytu Biopharma and Journey Medical are similar in size: $57.6m and $61.9m of revenue in their latest fiscal years. Journey Medical grew faster (10.2% against -13.3%). Journey Medical kept more of each dollar of sales as profit: a net margin of -18.5% against -24.8%.
| Latest fiscal year | Aytu BiopharmaAYTU, 2026 | Journey MedicalDERM, 2025 |
|---|---|---|
| Revenue | $57.6m | $61.9m |
| Revenue growth | -13.3% | 10.2% |
| Net income | −$14.3m | −$11.4m |
| Operating margin | — | -13.2% |
| Net margin | -24.8% | -18.5% |
| Return on equity | -52.6% | -44.0% |
| Free cash flow | $3.3m | −$12.4m |
| Cash | $26.3m | $24.1m |
| Total debt | $17.0m | $26.3m |
| Debt to equity | — | 82.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 76 | 58 |
| Market value | $20.8m | $129m |
| Price vs our value range | — | — |
| Moat score | 27 (Weak) | 35 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |